In the context of appetite regulation, acylation clearly enhances the therapeutic benefits of GLP-1R agonism (72), suggesting that the ability to cross the BBB is not critical for GLP-1R agonists to access functionally relevant sites for their anti-obesity action. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.